ea0070aep724 | Pituitary and Neuroendocrinology | ECE2020
Vitali Eleonora
, Boemi Ilena
, Piccini Sara
, Tarantola Giulia
, Zerbi Alessandro
, Smiroldo Valeria
, Lavezzi Elisabetta
, Spada Anna
, Mantovani Giovanna
, Lania Andrea
Treatment options for neuroendocrine tumors (NET), including everolimus, are rarely curative, as NETs frequently show resistance to medical therapy. In fact, the use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signalling. Metformin seems to have anticancer effects in neuroendocrine tumors (NETs). A recent retrospective study found longer progression-free-survival in diabetic pancreatic neuroendocrine tumo...